Drug Trial Radar · NCT07230132
Efficacy and Safety of ZT006 in Overweight and Obese Participants
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
184
Actual
Start
Dec 12, 2025
Primary completion
Dec 12, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Beijing QL Biopharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy and safety of ZT006 tablet in participants with overweight and obesity. In addition to dietary caloric restriction and increased physical activity, study participants will receive either ZT006 tablets or placebo tablets once every morning (placebo looks like ZT006 tablets but has no active pharmaceutical ingredients). For a fair comparison, study participants are assigned to ZT006 or placebo randomly by a computer. The study consists of a main study and an extension period. The treatment of the main study will last for 28 weeks. ZT006 tablets will be administered daily in an up-titration fashion, i.e. the dose of ZT006 will be gradually increased to reach three target doses (low, medium, high) so that the participants can tolerate its effect. Participants will have 17 clinic visits including one screening visit and one follow-up visit. The extension study will be conducted only in participants assigned to the low and medium dose groups in the main study. The treatment of the extension period will be 12 weeks. Female participants who are pregnant, breast-feeding or who plan to become pregnant during the study are not allowed to participate in the study. Pregnancy will be checked by blood or urine tests during the study.
Conditions
- Overweight , Obesity
Interventions
ZT006Drug
Participants will receive a daily dose of ZT006
Placebo of ZT006Drug
Participants will receive a daily dose of placebo of ZT006
ZT006Drug
Participants will receive a weekly dose of ZT006
ZT006Drug
Participants will receive a weekly dose of ZT006
ZT006Drug
Participants will receive a weekly dose of ZT006
ZT006Drug
Participants will receive a weekly dose of ZT006
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in body weight relative to baselineTime frame: Percentage-point from baseline to end of treatment (week 28)of the main study
- Rate of treatment-emergent adverse events in the extension periodTime frame: From week 28 to week 45
- Rate of serious adverse events in the extension periodTime frame: From week 28 to week 45
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Handan First Hospital
Handan, Hebei, China
Hebei Petro China Central Hospital
Langfang, Hebei, China
Harbin Medical University Affiliated Fourth Hospital
Harbin, Heilongjiang, China
Luoyang Third People's Hospital
Luoyang, Henan, China
The First People's Hospital of Chenzhou
Chenzhou, Hunan, China
YueYang People's Hospital
Yueyang, Hunan, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Central Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Xi'an Daxing Hospital
Xi’an, Shanxi, China
Huzhou Central Hospital
Huzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.